Results 201 to 210 of about 34,587 (240)

Management of Medullary Thyroid Cancer

Endocrinology and Metabolism Clinics of North America, 2019
Medullary thyroid cancer (MTC) is rare but aggressive. It can be cured only if intrathyroid at diagnosis. MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC ...
David Viola, Rossella Elisei
exaly   +4 more sources

Medullary Thyroid Cancer

2021
In this chapter while following the clinical course of a patient diagnosed with medullary thyroid cancer (MTC), the reader will be acquainted with the basic clinical features, diagnosis, and treatment of this rare tumor.
openaire   +1 more source

Medullary thyroid cancer

2017
Sažeti prikaz nastanka, kliničke slike, dijagnosticiranja i liječenja medularnog karcinoma štitne žlijezde.
Kusić, Zvonko, Dabelić, Nina, Gall Trošelj, Koraljka, Bedeković, Vladimir, Kovačić, Ksenija, Šarčević, Božena, Franceschi, Maja, Mateša, Neven   +7 more
openaire   +1 more source

[Medullary thyroid cancer].

Wiener klinische Wochenschrift, 1983
This paper attempts to review current opinions on medullary thyroid carcinoma. Histologically described for the first time in 1951 belongs to the endocrine-secreting group of tumours (APUD). It can be sporadic as well as hereditary. The histological classification nowadays is increasingly performed immunohistologically via calcitonin.
K, Keminger, R, Kokoschka, E, Schmalzer
openaire   +1 more source

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

New England Journal of Medicine, 2023
Ravinder Singh, Victoria Soldatenkova
exaly  

Medullary Thyroid Cancer

2009
Rebecca S. Sippel, Herbert Chen
  +4 more sources